clinical trial · NCT07470125
Bioequivalence (BE) Study Between YHP2511 and YHP2511A in Healthy Volunteers
Healthy SubjectsYHP2511YHP2511A
brief summary
A randomized, open-label, single-dose, 2-sequence, 2-period, crossover clinical trial to investigate the bioequivalence between YHP2511 and YHP2511A in healthy volunteers
started
Jun 23, 2026
primary completion
Jul 11, 2026
completion
Jul 11, 2026
last updated
Mar 13, 2026
detailed description
60 healthy subjects will be randomized to one of the 2 groups in the same ratio.
Subjects in group 1 will be administered "comparator" and "YHP2511" by crossover design on period 1, 2. Subjects in group 2 will be administered "YHP2511" and "comparator" by crossover design on period 1, 2.
official title
An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Bioequivalence of YHP2511 With YHP2511A in Healthy Adult Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol